Truist has adjusted its price target for RadNet (RDNT, Financial), reducing it from $88 to $74, while maintaining a Buy rating. This change is part of a broader review in anticipation of the company's first-quarter results in the Healthcare Services sector.
Despite the lowered target, Truist highlights the sector's strong position in a changing market landscape. Key attributes include its extensive domestic presence, robust free cash flow generation, and its defensive posture. While regulatory changes remain under scrutiny, the recent Medicare Advantage final rule aligns with expectations for a more favorable operating environment, according to the analysis.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for RadNet Inc (RDNT, Financial) is $75.33 with a high estimate of $88.00 and a low estimate of $60.00. The average target implies an upside of 42.14% from the current price of $53.00. More detailed estimate data can be found on the RadNet Inc (RDNT) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, RadNet Inc's (RDNT, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for RadNet Inc (RDNT, Financial) in one year is $28.99, suggesting a downside of 45.3% from the current price of $53. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the RadNet Inc (RDNT) Summary page.
